Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms
Overview
Authors
Affiliations
Objective The effectiveness of everolimus for the management of pancreatic neuroendocrine neoplasms (PNENs), including the G3/NEC types, remains unclear. We therefore investigated the effectiveness of the drug for the management of PNENs. Methods We analyzed the progression-free survival (PFS) and overall survival (OS) associated with everolimus and factors influencing the PFS and OS. Results One hundred patients were evaluated. The PFS associated with the G1/G2 types tended to be significantly longer than that associated with the G3/NEC types [hazard ratio (HR), 0.45; p=0.005]. A multivariate analysis showed that the significant factors influencing the PFS were age (<65 years old; HR, 0.44; p=0.002), grade (G1/G2; HR, 0.42; p=0.006), everolimus treatment line (≤2nd; HR, 0.55; p=0.031), and presence of treatment with metformin (yes; HR, 0.29; p=0.044). The median OS was 63.8 months. In the multivariate analysis, the significant factors influencing the OS were grade (G1/G2; HR, 0.21; p<0.001), volume of liver metastasis (≤25%; HR, 0.27; p<0.001), everolimus treatment line (≤2nd; HR, 0.27; p<0.001), and presence of primary tumor resection (yes; HR, 0.33; p=0.005). Conclusion The effectiveness of everolimus in the management of G3/NEC types and prognoses tended to be poorer than those associated with the G1/G2 types. Everolimus combined with metformin and early-line treatment with everolimus may be effective for managing advanced PNENs.
Everolimus in the Treatment of Neuroendocrine Tumors: Lights and Shadows.
Medici B, Caffari E, Maculan Y, Benatti S, Piacentini F, Dominici M Biomedicines. 2025; 13(2).
PMID: 40002868 PMC: 11853220. DOI: 10.3390/biomedicines13020455.
Metformin in the treatment of colorectal cancer and neuroendocrine tumours.
Danilowska K, Picheta N, Krupska B, Rudzinska A, Burdan O, Szklener K Contemp Oncol (Pozn). 2024; 28(2):85-90.
PMID: 39421710 PMC: 11480908. DOI: 10.5114/wo.2024.142553.
Zhu L, Ye X, She Y, Liu W, Hasegawa K, Rossi R J Gastrointest Oncol. 2024; 15(2):689-709.
PMID: 38756630 PMC: 11094498. DOI: 10.21037/jgo-24-218.
Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope.
Giri S, Sahoo J World J Gastroenterol. 2024; 30(12):1670-1675.
PMID: 38617746 PMC: 11008371. DOI: 10.3748/wjg.v30.i12.1670.
Predictive Factors of Response to Streptozotocin in Neuroendocrine Pancreatic Neoplasms.
Fanciulli G, La Salvia A, Di Molfetta S, Cannavale G, Puliani G, Verrico M J Clin Med. 2023; 12(24).
PMID: 38137624 PMC: 10743702. DOI: 10.3390/jcm12247557.